Drugs / V-Endo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03340324 | Oct 2017 → Dec 2019 | endometriosis | Immunitor LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V-Endo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03340324 ↗ |
| Route | Oral | “When taken orally it is postulated to cause the immune tolerance and anti-inflammatory effect as a result” NCT03340324 ↗ |